|Videos|August 11, 2022
Novel Agents Under Investigation for Myelofibrosis
The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.
Advertisement
Advertisement
Trending on OncLive
1
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
4
Relacorilant Plus Nab-Paclitaxel and Bevacizumab Yields Clinically Meaningful in Platinum-Resistant Ovarian Cancer
5